Main article

For 2010, the G-2 Diagnostic Stock Index adds molecular diagnostics companies Cepheid (Sunnyvale, Calif.) and Sequenom (San Diego). The index is down 4 percent in the five weeks ended Feb. 12, with 14 stocks down in price, three up, and one unchanged. In comparison to the G-2 Index’s 4 percent drop, the Nasdaq and the S&P each lost 6 percent.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

March 2010 - Table of Contents

DTTR March 2010 (Full PDF Issue)

IVD Companies, Labs Expand Personalized Medicine Plays

SACGHS Finalizes Recommendations on Gene Patents

Navigenics Raises $18 Million from Investors Including P&G

CancerGuide Diagnostics Partners with LabCorp, Looks to Raise $10.5 Million

Agilent Divests Clinical Diagnostics Business Hycor Biomedical

With Focus on Clinical Toxicology and Forensic Testing, NMS Labs Succeeds as a ‘Lab’s Lab’

Special Focus: Personalized Medicine: Biomarker Could Help Treatment Selection for Rheumatoid Arthritis

Special Focus: Personalized Medicine: Geisinger and TGen Partner for Personalized Medicine Initiative

Special Focus: Personalized Medicine: Researchers Map Genetic Variations Across 26 Cancers

Special Focus: Personalized Medicine: Clarient Launches IHC Test to Aid in Selection of Lung Cancer Therapy

Special Focus: Personalized Medicine: Pfizer and Qiagen to Develop Companion Diagnostic for Brain Tumor Patients

Special Focus: Personalized Medicine: JAMA Study Finds Genetic Links to Lung Cancer Survival

Special Focus: Personalized Medicine: Genomic Health Introduces Colon Cancer Test

Surgical Pathology Topped $1 Billion in Part B Charges in ’08

Myriad Genetics Inks Deal with Mammography Reporting System to Identify Potential Patients

Medco Health Services Acquires DNA Direct

IVD Stocks Slip 4%; Cepheid, Sequenom Join Index

DTTR G2 Insider (March 2010)

Vanderbilt Launches CardioDX Test for Coronary Artery Disease